Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
Volition (NYSE AMERICAN: VNRX) announced that its Nu.Q® NETs H3.1 assay has been included as the sole biomarker in DETECSEPS, a French real-world program for early detection of sepsis funded under France 2030.
The DETECSEPS consortium received approximately €6.3 million (~$7.3 million) in government financing. Results cited show H3.1 accurately distinguishes sepsis from non-infectious inflammation, correlates with disease severity, and outperforms APACHE II and SOFA for ICU admission prognostic power. H3.1 can be run on the IDS i10® analyzer with results within one hour. The release highlights a potential national rollout and cites ~166 million annual sepsis cases as a large testing opportunity.
VolitionRx (NYSE AMERICAN: VNRX) announced the first commercial sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon in Lyon, France on November 25, 2025.
The order is to complete internal clinical certification ahead of introducing Nu.Q® into routine clinical practice for cancer management, with cited evidence that methylated nucleosome biomarkers at non‑small cell lung cancer (NSCLC) diagnosis correlate with survival and progression‑free survival and can help identify patients who may benefit from curative care.
Company executives described the sale as a commercialization milestone and a step toward clinical use and licensing of Nu.Q® in human cancer.
VolitionRx (NYSE AMERICAN: VNRX) reported third quarter 2025 results and a business update on November 13, 2025, and will host an earnings call on November 14, 2025 at 8:30 a.m. ET.
Key financials: Q3 revenue was $0.6 million (+32% YoY). Operating expenses were down 10% year‑over‑year for the quarter and 18% for the first nine months. Net loss decreased 8% for Q3 and 20% year‑to‑date. Net cash used in operations was $3.6 million in the quarter, down 33% YoY. Post‑quarter, the company received approximately $6.1 million net proceeds from a public offering.
Management highlighted new human agreements with Werfen (APS) and a co‑marketing/services deal with Hologic, ongoing discussions with ~10 diagnostics/liquid‑biopsy firms, and forthcoming peer‑reviewed publications including Capture‑Seq™ developments.
VolitionRx (NYSE AMERICAN: VNRX) will host its Third Quarter 2025 earnings and business update conference call on Friday, November 14, 2025 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time).
The call will be hosted by Louise Batchelor, Group Chief Marketing & Communications Officer, with Cameron Reynolds, President and Group CEO; Terig Hughes, Group CFO; and Dr. Jake Micallef, Chief Scientific Officer, discussing Q3 2025 financial and operating results and upcoming milestones.
Dial-in numbers, Conference ID 13757129, a live audio webcast link, and a telephone replay available through November 28, 2025 are provided for investors and analysts.
Volition (NYSE AMERICAN: VNRX) donated its Nu.Q® Vet Cancer Test to HOPE Animal-Assisted Crisis Response Dogs at the organization's annual conference in Virginia Beach on Oct. 17, 2025.
The donation provided screening for crisis-response canines—prioritizing earlier cancer detection for older dogs and high-risk breeds—while Volition and partners handled sample collection and processing. The company also promoted a free DVM360 webinar featuring veterinary oncologist Dr Sue Ettinger on clinical evidence, sample processing, result interpretation, and practice integration.
VolitionRx (NYSE AMERICAN: VNRX) priced an underwritten public offering on Oct 10, 2025 of 11,550,000 common shares with warrants to purchase up to 11,550,000 shares at a public offering price of $0.52 per share-plus-warrant (with $0.01 allocated to the warrant). Each warrant is exercisable immediately at $0.60 and expires five years after issuance. Volition granted the underwriter a 30-day option for an additional 1,732,500 shares with accompanying warrants. Expected aggregate gross proceeds before expenses are approximately $6.0 million, with potential additional proceeds of about $6.9 million if warrants are fully exercised. The offering is expected to close on or about Oct 14, 2025, with net proceeds for R&D, clinical studies, commercialization, working capital and potential acquisitions.
VolitionRx (NYSE AMERICAN: VNRX) announced a proposed underwritten public offering of its common stock and accompanying common stock purchase warrants on October 9, 2025. The company said it will grant the underwriter a 30‑day option to buy up to an additional 15% of the shares and warrants at the public offering price, subject to underwriting discounts and commissions.
Volition intends to use net proceeds for research and product development, clinical studies, commercialization, working capital and potential strategic acquisitions. Newbridge Securities Corporation is sole book‑running manager. The offering is being made from a Form S‑3 shelf registration declared effective on April 18, 2025, and final terms depend on market conditions.
VolitionRx (NYSE AMERICAN: VNRX) announces sponsorship of a GenomeWeb webinar titled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" scheduled for October 8, 2025.
The webinar will feature presentations from Dr. Eric Ariazi, discussing epigenetic pathways and cancer immunoediting, and Dr. Marielle Herzog, R&D director at Belgian Volition, who will present case studies on Nu.Q® assays. The event aims to showcase Volition's Nu.Q® Discover service for drug developers and scientists, focusing on epigenetic profiling in disease model development and clinical studies.
VolitionRx (NYSE AMERICAN: VNRX) has signed a co-marketing agreement with Hologic Diagenode for its Nu.Q® Discover service, which provides epigenetic profiling solutions for drug development and research. The initial one-year agreement could potentially lead to Hologic becoming an exclusive provider of these services.
The Nu.Q® Discover program has an estimated total addressable market of $200 million annually. The partnership leverages Hologic's extensive experience and large client base, having recorded revenues exceeding $4 billion in 2024. The collaboration aims to expand Volition's presence in the pharmaco-epigenetics market by incorporating nucleosome-based biomarkers into Hologic's portfolio for various disease areas including oncology, cardiovascular, and neurodegenerative conditions.
VolitionRx (NYSE AMERICAN: VNRX) has signed its first human out-licensing deal - a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center for Antiphospholipid Syndrome (APS) applications.
The agreement grants Werfen access to Volition's proprietary Nu.Q® H3.1 NETs assay components to investigate its clinical utility in APS patient management. Werfen has successfully transferred the Nu.Q® NETs assay to their ACL AcuStar® platform, with early results showing promise in detecting NETs levels in APS patients.
APS affects approximately 4 million people worldwide, causing increased blood clot risks and pregnancy complications. The Nu.Q® NETs test represents the first CE-IVD biomarker being investigated for APS, potentially offering improved diagnostic information and ongoing patient monitoring capabilities.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
